Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Compass Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2020
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0.85
0
Research and development
22.4
14.9
20.3
30
38.1
42.3
56
General and administrative
0.03
11.6
0.03
12.9
10.9
11.7
12.2
15.1
16.9
Operating expenses
34.1
27.8
81.9
41.7
50.4
57.5
72.8
Operating income
-0.03
-34.1
-0.03
-27.8
-81.9
-41.7
-50.4
-56.6
-72.8
Interest expense
0
1.23
0.01
0.91
0.37
0
Interest income
0.74
0.09
0.03
2.36
7.9
7.3
6.4
Other non-operating income
-0.6
-1.66
-0.3
2.43
7.87
7.25
6.35
Pre-tax income
-34.7
-29.5
-82.2
-39.2
-42.5
Income tax
0.09
0.03
0
0
0
0
0
Net income
-0.04
-34.7
-0.04
-29.5
-82.2
-39.2
-42.5
-49.4
-66.5
EBITDA
-32
-25.4
-81.3
-40.9
-49.7
-56
-72.6
EPS, basic
-0.01
-5.19
-0.01
-0.96
-1.31
-0.37
-0.33
-0.36
-0.42
EPS, diluted
-0.01
-5.19
-0.01
-0.96
-1.31
-0.37
-0.33
-0.36
-0.42
Shares, basic (weighted)
5
6.69
5
30.8
62.9
105
127
137
158
Shares, diluted (weighted)
5
6.69
5
30.8
62.9
105
127
137
158
Balance sheet
FY2019
FY2020
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0
25.3
0
47.1
145
34.9
24.2
43.5
30.6
Short-term investments
0
152
128
83.2
178
Other current assets
0.94
3.13
2.59
8.18
1.42
6.03
0.91
Total current assets
0
26.2
0
50.2
147
195
154
133
210
Property, plant and equipment
3.75
1.13
2.24
1.57
0.9
0.35
0.1
Lease right-of-use assets
0
4.09
2.97
1.78
6.73
9.1
Other non-current assets
0.13
0.32
0.32
0.32
0.32
0.57
Total assets
0
30.4
0
51.9
154
200
157
140
220
Accounts payable
0
0.63
0.01
1.06
0.87
3.38
4.09
2.25
1.59
Accrued liabilities
3.12
1.57
8.78
11.7
2.51
6.29
11.4
Short-term debt
5.58
7.47
0
Total current liabilities
0.08
9.82
0.11
10.1
10.6
16.2
7.8
8.87
14
Long-term debt
9.29
1.87
0
Lease liabilities
0
3.05
1.84
0.54
6.3
8.83
Total liabilities
0.08
19.1
0.11
12
13.7
18
8.34
15.2
22.8
Total debt
14.9
9.33
0
Paid-in capital
3.3
191
374
455
464
490
628
Retained earnings
-0.07
-122
-0.11
-151
-234
-273
-315
-365
-431
Other comprehensive income
0
-0.3
0.04
0.21
0.28
Shareholders' equity
-95.3
11.3
-125
39.9
140
182
149
125
197
Total equity
-95.3
11.3
-125
39.9
140
182
149
125
197
Total liabilities and equity
0
30.4
0
51.9
154
200
157
140
220
Shares outstanding
5
7.03
5
51.2
101
126
128
138
178
Cash flow statement
FY2019
FY2020
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-0.04
-34.7
-0.04
-29.5
-82.2
-39.2
-42.5
-49.4
-66.5
Depreciation and amortization
2.1
2.4
0.6
0.78
0.7
0.59
0.28
Stock-based compensation
0.92
4.02
4.03
5.33
6.12
8.56
8.37
Change in payables
0
-1.1
0.01
0.43
-0.19
2.52
0.71
-1.84
-0.66
Cash from operations
-0.03
-31.7
-0.03
-26.8
-19.7
-34.1
-40.6
-44.9
-49.1
Capital expenditures
-0.47
-0.11
-1.57
-0.21
-0.03
-0.04
-0.03
Acquisitions
-0.32
0
Purchases of investments
0
-200
-155
-88.2
-195
Sales and maturities of investments
0
49
182
135
101
Cash from investing
-0.47
0.04
-1.77
-151
27
46.8
-93.3
Debt repaid
-5.63
-9.38
0
Stock issued
60.5
128
76.2
3.13
18.1
138
Cash from financing
0.04
0.03
48.5
119
75.8
2.94
17.3
130
Net change in cash
0
-32.2
-0
21.8
97.2
-110
-10.7
19.3
-12.8
Free cash flow
-32.2
-26.9
-21.2
-34.3
-40.6
-44.9
-49.2
Interest paid
1.12
0.85
0.37
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.13 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-44.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-38.6%
Net income / average total assets.
Return on invested capital (ROIC)
-49.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
57.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
2.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
37.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
56.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
3.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
33.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
14.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
14.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
38.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.2x
Current assets / current liabilities.
Quick ratio
11.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.2x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.30
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.30
Cash from operations / diluted weighted shares.
Book value per share
$0.92
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.23x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.23x
Market cap / tangible book value, when positive.
FCF yield
-27.7%
Free cash flow / market cap.
Earnings yield
-36.1%
Net income / market cap (the inverse of P/E).
What was Compass Therapeutics, Inc.'s revenue in fiscal 2025?
Compass Therapeutics, Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was Compass Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $66.5M.
How much free cash flow did Compass Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $49.1M minus capital expenditures of $25.0K left free cash flow of -$49.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.